FDA approves MagVita TMS Therapy system for depression-MagVenture
The FDA cleared the MagVita TMS Therapy system, from MagVenture, for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. The procedure has been proven safe and effective and MagVenture is the fourth company since 2008 to receive clearance to market devices for the emerging brain stimulation technique.
MagVita TMS Therapy system is a complete system for effectively treating depression. It can perform repetitive Transcranial Magnetic Stimulation (rTMS) and run many protocols successively (up to 20.000 pulses).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.